Is Dermata Therapeutics Inc. (NASDAQ: DRMA) Hit More of the Losses Given A -1020.97% Dip From High? – Marketing Sentinel
Home  »  Business   »  Is Dermata Therapeutics Inc. (NASDAQ: DRMA) Hit Mo...

Is Dermata Therapeutics Inc. (NASDAQ: DRMA) Hit More of the Losses Given A -1020.97% Dip From High?

During the last session, Dermata Therapeutics Inc. (NASDAQ:DRMA)’s traded shares were 0.19 million. At the end of the trading day, the stock’s price was $0.62, reflecting an intraday loss of -3.09% or -$0.02. The 52-week high for the DRMA share is $6.95, that puts it down -1020.97 from that peak though still a striking 29.03% gain since the share price plummeted to a 52-week low of $0.44. The company’s market capitalization is $5.87M, and the average intraday trading volume over the past 10 days was 0.67 million shares, and the average trade volume was 1.38 million shares over the past three months.

Dermata Therapeutics Inc. (DRMA) received a consensus recommendation of a Buy from analysts. That translates to a mean rating of 2.00. DRMA has a Sell rating from 0 analyst(s) out of 1 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 1 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -$0.32.

Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .

Sponsored

Dermata Therapeutics Inc. (NASDAQ:DRMA) trade information

Dermata Therapeutics Inc. (DRMA) registered a -3.09% downside in the last session and has traded in the green over the past 5 sessions. The stock plummet -3.09% in intraday trading to $0.62 this Friday, 08/05/22, hitting a weekly high. The stock’s 5-day price performance is 6.69%, and it has moved by -10.16% in 30 days. The short interest in Dermata Therapeutics Inc. (NASDAQ:DRMA) is 55720.0 shares and it means that shorts have 0.02 day(s) to cover.

The consensus price target of analysts on Wall Street is $4.00, which implies an increase of 84.5% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $4.00 and $4.00 respectively. As a result, DRMA is trading at a discount of -545.16% off the target high and -545.16% off the low.

Dermata Therapeutics Inc. (DRMA) estimates and forecasts

Statistics show that Dermata Therapeutics Inc. has outperformed its competitors in share price, compared to the industry in which it operates. Dermata Therapeutics Inc. (DRMA) shares have gone down -71.02% during the last six months, with a year-to-date growth rate more than the industry average at 27.98% against 1.00. Yet analysts are ramping up their growth forecast for the fiscal year 2022. Revenue is predicted to grow 54.30% this quarter and then jump 67.40% in the quarter after that.

While earnings are projected to return -223.30% in 2022.

DRMA Dividends

Dermata Therapeutics Inc. is due to release its next quarterly earnings in September. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.

Dermata Therapeutics Inc. (NASDAQ:DRMA)’s Major holders

Dermata Therapeutics Inc. insiders own 43.79% of total outstanding shares while institutional holders control 10.67%, with the float percentage being 18.98%. Geode Capital Management, LLC is the largest shareholder of the company, while 14 institutions own stock in it. As of Mar 30, 2022, the company held over 26666.0 shares (or 0.29% of all shares), a total value of $33332.0 in shares.

The next largest institutional holding, with 17669.0 shares, is of Blackrock Inc.’s that is approximately 0.19% of outstanding shares. At the market price on Mar 30, 2022, these shares were valued at $22086.0.

Also, the Mutual Funds coming in first place with the largest holdings of Dermata Therapeutics Inc. (DRMA) shares are Fidelity NASDAQ Composite Index Fund and Fidelity Extended Market Index Fund. Data provided on May 30, 2022 indicates that Fidelity NASDAQ Composite Index Fund owns about 15860.0 shares. This amounts to just over 0.17 percent of the company’s overall shares, with a $12373.0 market value. The same data shows that the other fund manager holds slightly less at 10806.0, or about 0.12% of the stock, which is worth about $8430.0.

Leave a Comment

Your email address will not be published.

On Key

Related Posts

[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]